Phase I study of the Bcl-2 inhibitor venetoclax with DA-EPOCH-R as initial therapy for aggressive B-cell lymphomas.

Sarah C. Rutherford,Jeremy S. Abramson,Nancy L. Bartlett,Stefan K. Barta,Nadia Khan,Robin Joyce,Kami J. Maddocks,Ying Yuan,Trisha Ali-Shaw,Silvia Senese,Jason R. Westin,John P. Leonard

Phase I study of the Bcl-2 inhibitor venetoclax with DA-EPOCH-R as initial therapy for aggressive B-cell lymphomas.

2020

Sarah C. Rutherford
Jeremy S. Abramson
Nancy L. Bartlett
Stefan K. Barta
Nadia Khan
Robin Joyce
Kami J. Maddocks
Ying Yuan
Trisha Ali-Shaw
Silvia Senese
Jason R. Westin
John P. Leonard

8003Background: Dose-adjusted (DA) EPOCH-R is a frontline treatment for aggressive B-cell lymphomas. Bcl-2 is associated with chemoresistance due to BCL2 gene rearrangement or protein overexpressio...

Keywords:

Venetoclax
B cell
phase i study
Pathology
initial therapy
Series (stratigraphy)
Medicine
Bcl-2 Inhibitor
Cancer research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations